Pdp (68071 3764 9)
This description is not available.*
Leflunomide Tablet, Film Coated
Product Images NDC 68071-3764
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 68071-3764). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 01)
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 02)
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 03)
The text is not readable.*
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 04)
This text refers to the percentage of ACR responders over time as per Trial 1. It mentions the method of "Last Observation Carried Forward" which is a technique used in statistical analysis.*
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 05)
The text provided lists different treatment options represented by codes such as L for Leflunomide, M for Methotrexate, S for Sulfasalazine, and P for Placebo, along with a Change in Sharp Score over different time periods (12 months, 8 months, and 12 months). The Sharp Score is used to evaluate radiographic progression in patients with rheumatoid arthritis. The document seems to compare the effectiveness of these treatments based on their impact on the Sharp Score.*
Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 06)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
